Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in Foster City, California.
IPO Year: 2020
Exchange: NASDAQ
Website: vaxcyte.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/22/2025 | Overweight | Cantor Fitzgerald | |
| 12/20/2024 | $135.00 | Buy | Goldman |
| 12/7/2023 | $69.00 | Buy | Mizuho |
| 4/18/2023 | Outperform | TD Cowen | |
| 1/3/2023 | $52.00 → $58.00 | Buy | Needham |
| 12/15/2022 | $66.00 | Buy | Guggenheim |
| 11/17/2022 | $69.00 | Buy | BTIG Research |
| 12/29/2021 | $50.00 | Buy | Jefferies |
| 6/24/2021 | $50.00 | Buy | Jefferies |
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Three-Dose Immunization Series Expected in Mid-2026, With Complete Booster Data Up to Nine Months Later -- -- Company Expects to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Announced VAX-XL, Third-Generation Pneumococcal Conjugate Vaccine Candidate Desig
SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. "We are thrilled to welcome Olivier to Vaxcyte's Board of Directors," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market.
-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formu
SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants. To participate in the conference call, p
-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series of VAX-24 Infant Phase 2 Study by the End of First Quarter, Followed by Topline Data from Booster Dose by the End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series Expected in Mid-2026, Followed by Topline Data from Booster Dose A
SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. To participate in the conference call, please dial 800-225-9448 (domestic) or 203-518-9708 (international) and refer to conference ID PCVXQ424. A live webcast
-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later -- -- VAX-31 is Designed to Cover Approximately 94% of Invasive Pneumococcal Disease and Approximately 93% of Acute Otitis Media in U.S. Children Under Five -- -- Company Remains on Track to Announce VAX-24 Phase 2 Infant Study Topline Data from Primary Immunization Series by End of First Quarter of 2025 -- -- VAX-31 and VAX-24 Offer Potential to Protect Vulne
SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference in New York on Thursday, February 6, 2025 at 9:30 a.m. ET / 6:30 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company's website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About VaxcyteVaxcyte is a vacc
-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later -- -- VAX-31 is Designed to Cover Approximately 94% of Invasive Pneumococcal Disease and Approximately 93% of Acute Otitis Media in U.S. Children Under Five -- -- VAX-31 Offers Potential to Protect Vulnerable Population by Providing Greater Coverage Against Both Currently Circulating and Historically Prevalent Strains Relative to Standard-Of-Care Pneumococcal Conjugate Vaccines -- -- Company Remains on Track to Announce VAX-24 Phase 2 Infant Stu
-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: Breakthrough Therapy Designation Granted by FDA; Company Plans to Initiate Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 -- -- VAX-31, Designed to Cover Currently Circulating and Historically Prevalent Strains, is Being Studied for the Prevention of Invasive Pneumococcal Disease in the Pediatric and Adult Populations -- SAN CARLOS, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines
SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
10-Q - Vaxcyte, Inc. (0001649094) (Filer)
8-K - Vaxcyte, Inc. (0001649094) (Filer)
SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
8-K - Vaxcyte, Inc. (0001649094) (Filer)
DEFA14A - Vaxcyte, Inc. (0001649094) (Filer)
DEF 14A - Vaxcyte, Inc. (0001649094) (Filer)
PRE 14A - Vaxcyte, Inc. (0001649094) (Filer)
8-K - Vaxcyte, Inc. (0001649094) (Filer)
144 - Vaxcyte, Inc. (0001649094) (Subject)
4 - Vaxcyte, Inc. (0001649094) (Issuer)
3 - Vaxcyte, Inc. (0001649094) (Issuer)
3 - Vaxcyte, Inc. (0001649094) (Issuer)
4 - Vaxcyte, Inc. (0001649094) (Issuer)
4 - Vaxcyte, Inc. (0001649094) (Issuer)
4 - Vaxcyte, Inc. (0001649094) (Issuer)
4 - Vaxcyte, Inc. (0001649094) (Issuer)
4 - Vaxcyte, Inc. (0001649094) (Issuer)
4 - Vaxcyte, Inc. (0001649094) (Issuer)
4 - Vaxcyte, Inc. (0001649094) (Issuer)
Cantor Fitzgerald initiated coverage of Vaxcyte with a rating of Overweight
Goldman initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $135.00
Mizuho initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $69.00
TD Cowen initiated coverage of Vaxcyte with a rating of Outperform
Needham reiterated coverage of Vaxcyte with a rating of Buy and set a new price target of $58.00 from $52.00 previously
Guggenheim initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $66.00
BTIG Research initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $69.00
Jefferies resumed coverage of Vaxcyte with a rating of Buy and set a new price target of $50.00
Jefferies resumed coverage of Vaxcyte with a rating of Buy and set a new price target of $50.00
SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formu
SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants. To participate in the conference call, p
SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. To participate in the conference call, please dial 800-225-9448 (domestic) or 203-518-9708 (international) and refer to conference ID PCVXQ424. A live webcast
-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity Criteria for All 31 Serotypes -- -- At All Doses Studied, VAX-31 Was Observed to be Well Tolerated and Demonstrated a Safety Profile Similar to Prevnar 20® -- -- Topline Results Further Validate Potential of Vaxcyte's Carrier-Sparing Platform to Deliver Broadest-Spectrum Pneumococcal Conjugate Vaccine Candidates that Provide Protection Against Both Currently Circulating and Historically Prevalent Serotypes -- -- For Adult Indication, VAX-31 Selected to Advance to Phase 3 Program; Vaxcyte Plans
SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, September 3, 2024, at 8:00 a.m. Eastern Time to present topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the Company's 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older. To participate in the conference call, please dial 800-225-9448 (domest
SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2023 after market close on February 27, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. To participate in the conference call, please dial (800) 225-9448 (domestic) or (203) 518-9708 (international) and refer to conference ID PCVXQ423. A live we
-- VAX-24 Showed Robust Immune Responses Across all 24 Serotypes (ST) at All Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64 -- -- VAX-24 2.2mcg Dose Met Opsonophagocytic Activity (OPA) Response Non-Inferiority Criteria for 18 of 20 STs Common with Prevnar 20® (PCV20) and Superiority Criteria for the Four Additional VAX-24 STs -- -- VAX-24 2.2mcg Dose Showed Further Improvement in Overall Immune Responses vs. PCV20 Relative to Results from Phase 2 Study in Adults Aged 50-64 -- -- Full Six-Month Safety Data from Both Adult Studies Demonstrated VAX-24 Safety and Tolerability Results Similar to PCV20 at All Doses Studied -- -- Prespecified Pooled Immunogenicity Analyses of Data
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, April 17, 2023, at 7:30 a.m. Eastern Time to discuss results from the Phase 2 study of VAX-24, the Company's lead, broad-spectrum 24-valent pneumococcal conjugate vaccine (PCV) candidate, in adults aged 65 and older and full six-month safety data from both adult Phase 2 studies. To participate in the conference call, please dial (800)-267-6316 (domestic) or (203)-518-9783 (international) and refe
SAN CARLOS, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on February 27, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. A live webcast of the conference ca
-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20™ (PCV20) at All Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2mcg PCV Dose Met or Exceeded Regulatory Immunogenicity Standards -- -- All 20 VAX-24 Serotypes Common with PCV20 Met Standard OPA Response Non-Inferiority Criteria, of Which 16 Achieved Higher Immune Responses, at 2.2mcg VAX-24 Dose -- -- All 4 Serotypes Unique to VAX-24 Exceeded Standard Superiority Criteria -- -- Vaxcyte to Advance Potential Best-in-Class VAX-24 Clinical Program in Adult and Pediatric Populations -- -- Company to Host Webcast/Conference Call Today at 8:00 a.m. ET / 5:00 a.m. PT -- SA
SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. "We are thrilled to welcome Olivier to Vaxcyte's Board of Directors," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market.
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Board of Directors. "We are thrilled to welcome John to Vaxcyte's Board of Directors and look forward to benefiting from his wealth of biopharmaceutical and vaccine expertise, including the manufacture, supply and commercialization of pneumococcal conjugate vaccines (PCVs)," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "As we continue to progress our PCV candidates, VAX-24
-- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Whitney Jones as Chief People Officer. Ms. Jones will lead Vaxcyte's human resources strategy and operations, including people and culture, talent acquisition and management, learning and development, total rewards and employee engagement. "At Vaxcyte, we are proud to cultivate a culture that values coll
SAN CARLOS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Jacks Lee to its Board of Directors. "We are pleased to welcome Jacks, an accomplished industry leader with extensive biopharmaceutical and vaccine manufacturing, supply and operations expertise, to Vaxcyte's Board of Directors as we continue to realize our mission of developing vaccines to address serious bacterial illnesses," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "Jacks will provide strategic insights across
-- Vaxcyte has Appointed Mark Wiggins, M.B.A. as Chief Business Officer and Jakub Simon M.D., M.S. as Chief Medical Officer as the Company Prepares to Enter Next Phase of Growth -- SAN CARLOS, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Mark Wiggins as Chief Business Officer and Jakub Simon as Chief Medical Officer. Both Mark and Jakub are accomplished industry leaders who bring vast expertise that will support the continued growth and advancement of the Company. "We are delighted to
BOTHELL, Wash., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Grant Pickering to its Board of Directors. Mr. Pickering is Chief Executive Officer, co-founder and member of the Board of Directors at Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. "Grant is an accomplished life sciences leader with considerable experience across all stages of development and commercialization of new med
-- Company Expects to Submit VAX-24 IND Application to FDA in Q1 2022 -- -- Completed Manufacture of VAX-24 GMP Drug Product and GLP Toxicology Study -- FOSTER CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the third quarter ended September 30, 2021 and provided a business update. "We continue to make meaningful progress with the IND-enabling activities for VAX-24, our lead, 24-valent pneumococcal conjugate vaccine (PCV
FOSTER CITY, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced it has appointed Carlos Paya and Michael Kamarck, accomplished industry leaders, to its board of directors. Dr. Paya will also serve as the Board Chair. Kurt von Emster, a longtime director who served as Interim Chair, will remain on the board. "We are pleased to have Carlos and Michael join our board of directors to help us scale and advance our business to deliver next-generation vaccines
FOSTER CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the second quarter ended June 30, 2021 and provided a business update. "The public health community continues to affirm the need for vaccines that can offer broader protection to prevent pneumococcal disease and, importantly, reach an expanded population including adults aged 50 and older as well as those at higher risk due to existing health conditions," said Grant Pi